United Therapeutics
UTHR
321 hedge funds and large institutions have $9.25B invested in United Therapeutics in 2013 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 121 increasing their positions, 115 reducing their positions, and 24 closing their positions.
140% more funds holding in top 10
Funds holding in top 10: 5 → 12 (+7)
121% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 24
44% more capital invested
Capital invested by funds: $6.43B → $9.25B (+$2.81B)
10% more funds holding
Funds holding: 293 → 321 (+28)
5% more repeat investments, than reductions
Existing positions increased: 121 | Existing positions reduced: 115
28% less call options, than puts
Call options by funds: $16.7M | Put options by funds: $23.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Herndon Capital Management
Atlanta,
Georgia
|
+$70M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$40.3M |
| 3 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
+$34.3M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$24.7M |
| 5 |
WCM
Winton Capital Management
London,
United Kingdom
|
+$24.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
-$1.13B |
| 2 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$49.7M |
| 3 |
TSW
Thompson Siegel & Walmsley
Richmond,
Virginia
|
-$36.2M |
| 4 |
NAP
New Amsterdam Partners
New York
|
-$32.3M |
| 5 |
AC
Amici Capital
New York
|
-$24.2M |
UTHR Hedge Fund Activity: Q4 2013 in Review
321 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q4 2013, worth a combined $9.25B — up 44% from $6.43B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new UTHR positions and 24 closed out — a net gain of 29 holders — while 121 added to existing stakes and 115 trimmed.
The largest buyer was Herndon Capital Management, adding an estimated $70M. The largest seller was BNP Paribas Financial Markets, cutting an estimated $1.13B.
- 321 institutional investors held United Therapeutics (UTHR) as of Q4 2013, up from 293 in Q3 2013.
- Funds reported $9.25B of United Therapeutics stock for Q4 2013, up 44% quarter-over-quarter.
- 53 funds opened new United Therapeutics positions in Q4 2013 and 24 closed out, a net change of +29 holders.
- The largest United Therapeutics buyer in Q4 2013 was Herndon Capital Management, an estimated $70M added.
- The largest United Therapeutics seller in Q4 2013 was BNP Paribas Financial Markets, an estimated $1.13B sold.
Based on aggregated 13F filings for Q4 2013.